By expenditures
| Name | Title | Type |
|---|---|---|
| Kathy Sabitsky | Finance Director | Auditee |
| Sandra Seres | Executive Director | Auditee |
| James Traester | Cpa / Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 363429 | 2024 | 2025-07-31 | Apicella Testa & Company PC | $1.65M |
| 316325 | 2023 | 2024-07-31 | Apicella Testa & Company PC | $1.62M |
| 35487 | 2022 | 2023-08-21 | Apicella Testa and Company | $1.46M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 363429 | 2024 | 2025-07-31 | 1148798 | 2024-001 | Material Weakness | Yes | AB |
| 363429 | 2024 | 2025-07-31 | 1148797 | 2024-001 | Material Weakness | Yes | AB |
| 363429 | 2024 | 2025-07-31 | 572356 | 2024-001 | Material Weakness | Yes | AB |
| 363429 | 2024 | 2025-07-31 | 572355 | 2024-001 | Material Weakness | Yes | AB |
| 316325 | 2023 | 2024-07-31 | 1056246 | 2023-002 | Significant Deficiency | Yes | C |
| 316325 | 2023 | 2024-07-31 | 1056245 | 2023-002 | Significant Deficiency | Yes | C |
| 316325 | 2023 | 2024-07-31 | 1056244 | 2023-001 | Material Weakness | Yes | AB |
| 316325 | 2023 | 2024-07-31 | 1056243 | 2023-001 | Material Weakness | Yes | AB |
| 316325 | 2023 | 2024-07-31 | 479804 | 2023-002 | Significant Deficiency | Yes | C |
| 316325 | 2023 | 2024-07-31 | 479803 | 2023-002 | Significant Deficiency | Yes | C |
| 316325 | 2023 | 2024-07-31 | 479802 | 2023-001 | Material Weakness | Yes | AB |
| 316325 | 2023 | 2024-07-31 | 479801 | 2023-001 | Material Weakness | Yes | AB |
| 35487 | 2022 | 2023-08-21 | 610323 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 610255 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 610254 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 610253 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 610252 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 610251 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 610250 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 610249 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 610248 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 610247 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 610246 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 610245 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 610244 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 610243 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 610242 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 610241 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 33881 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 33813 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 33812 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 33811 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 33810 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 33809 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 33808 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 33807 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 33806 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 33805 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 33804 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 33803 | 2022-001 | Material Weakness | - | P |
| 35487 | 2022 | 2023-08-21 | 33802 | 2022-004 | - | - | P |
| 35487 | 2022 | 2023-08-21 | 33801 | 2022-003 | Significant Deficiency | - | C |
| 35487 | 2022 | 2023-08-21 | 33800 | 2022-002 | Material Weakness | - | AB |
| 35487 | 2022 | 2023-08-21 | 33799 | 2022-001 | Material Weakness | - | P |